Regulus Therapeutics (RGLS)

BiotechSign Signal Grade

Pipeline Overview

Therapeutic Focus

Fibrosissrc

Clinical Trial Activity

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Recent News & SEC Filings

• SEC 8-K 8-K - Current report 2025-06-25T09:12 · SEC EDGAR
• SEC 8-K 8-K - Current report 2025-05-08T16:15 · SEC EDGAR
• SEC 8-K 8-K - Current report 2025-04-30T08:27 · SEC EDGAR
• SEC 8-K 8-K - Current report 2025-03-27T07:15 · SEC EDGAR
• SEC 8-K 8-K - Current report 2025-03-13T16:15 · SEC EDGAR

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

• Pharmacokinetics, Safety, and Tolerability of Anti-miR-17 Oligonucleotide RGLS4326 in Healthy Adult Subjects. — J Clin Pharmacol 2026 May Owen T PMID 42132413
• Recommendations for pre-analytical urine sample handling to allow optimal assessment of albuminuria and proteinuria. — Nephrol Dial Transplant 2026 Aug 25 Ridderbos S PMID 42029072
• Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. — Hepatol Commun 2026 May 1 Gordon SC PMID 41974026
• Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial. — EBioMedicine 2026 May Stylianakis E PMID 41934919
• Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. — JAMA 2026 Mar 3 Giamarellos-Bourboulis EJ PMID 41359996

Primary Sources

• Company identity
• Therapeutic indication
• Clinical trial aggregate
• Publication 42132413
• Publication 42029072
• Publication 41974026
• Publication 41934919
• Publication 41359996